#United States #New York #Class Action #Kahn Swick #Beta Bionics

Beta Bionics Class Action Lawsuit Notice

Investors in Beta Bionics, Inc. are being alerted to an upcoming opportunity to join a class action lawsuit aimed at recovering losses incurred between July 30, 2025, and February 24, 2026. The deadline for applying to be part of this legal action is set for November 3, 2026. This notice comes from Kahn Swick & Foti, LLC (KSF), led by former Louisiana Attorney General Charles C. Foti, Jr.

Background

The lawsuit is currently filed in the United States District Court for the Central District of California and aims to address the alleged misstatements and omissions made by Beta Bionics regarding its business operations. The core of the complaint indicates that the company's public disclosures did not adequately inform investors about serious issues linked to their flagship product, the iLet Bionic Pancreas insulin pump.

Key Allegations

According to the lawsuit:
1. Beta Bionics is accused of not revealing that the iLet device utilized a malfunctioning automated dosing system. This flaw reportedly led to dangerous spikes in insulin delivery, putting patients at risk for severe hypoglycemic incidents requiring hospitalization.
2. The company allegedly received thousands of customer complaints regarding the device but failed to report these to the U.S. Food and Drug Administration (FDA) in a timely manner.
3. Furthermore, it is claimed that the FDA Form 483, issued to the company in June 2025, identified over 18,000 unreported complaints, a fact that was misrepresented to investors.
4. The legal filing also suggests that Beta Bionics did not properly address these issues, leading to FDA warnings regarding their quality management processes and device reporting protocols.
5. As a result, the lawsuit alleges that positive representations made by the company regarding its performance and business outlook were misleading.

What Investors Should Do

If you purchased Beta Bionics stock during the defined class period and suffered financial losses, you have until November 3, 2026, to file for lead plaintiff status in the pending class action. Importantly, even if you do not become a lead plaintiff, you can still participate in any potential recovery.

For those interested in pursuing this opportunity, more information is available by contacting Lewis Kahn at KSF. Investors can reach him at 1-833-538-3666 or via email at email protected]. Additional details can also be found on their [website.

About Kahn Swick & Foti, LLC

Kahn Swick & Foti is recognized as one of the leading boutique securities litigation firms in the United States, focusing on recovering investor losses due to corporate misconduct. The firm boasts a network of offices across major U.S. cities, providing expert legal support to various investors.

This class action serves not only as a call to action for investors affected by Beta Bionics but also underscores the importance of transparency and accountability in the medical device industry. As the November deadline approaches, affected individuals are encouraged to act swiftly to protect their interests.